Veracyte (12V) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

12V Analyst Ratings

Moderate Buy

8 Buy

1 Hold

1 Sell

Based on 10 analysts giving stock ratings to

Veracyte

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

12V Stock 12 Month Forecast

Average Price Target

€52.16

▲(40.34% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Veracyte in the last 3 months. The average price target is €52.16 with a high forecast of €61.53 and a low forecast of €39.23. The average price target represents a 40.34% change from the last price of €37.17.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"€25","62":"€62","34.25":"€34.3","43.5":"€43.5","52.75":"€52.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":61.52589585,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€61.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.163259525,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€52.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.2339046,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€39.23</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,34.25,43.5,52.75,62],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,41.67,43.19737660384615,44.72475320769231,46.25212981153846,47.77950641538462,49.30688301923077,50.834259623076925,52.361636226923075,53.88901283076923,55.41638943461538,56.94376603846154,58.47114264230769,59.99851924615385,{"y":61.52589585,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,41.67,42.47717380961539,43.28434761923077,44.09152142884616,44.89869523846154,45.70586904807693,46.51304285769231,47.32021666730769,48.127390476923075,48.93456428653846,49.741738096153846,50.54891190576923,51.356085715384616,{"y":52.163259525,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,41.67,41.48260804615385,41.2952160923077,41.10782413846154,40.920432184615386,40.733040230769234,40.54564827692308,40.35825632307692,40.17086436923077,39.98347241538462,39.796080461538466,39.60868850769231,39.421296553846155,{"y":39.2339046,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.8,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.74,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.42,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.62,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.68,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.68,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.67,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€61.53

Average Price Target€52.16

Lowest Price Target€39.23

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Westenberg

Piper Sandler

€48.15

Buy

29.54%

Upside

Reiterated

09/17/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Veracyte (NASDAQ: VCYT), IQVIA Holdings (NYSE: IQV) and Chemed (NYSE: CHE)

William Bonello

Craig-Hallum

―

Buy

―

Reiterated

09/15/26

Analysts Offer Insights on Healthcare Companies: OmniAb (NASDAQ: OABI), Veracyte (NASDAQ: VCYT) and Rocket Pharmaceuticals (NASDAQ: RCKT)

Matt Larew

William Blair

―

Buy

―

Reiterated

09/15/26

Analysts Offer Insights on Healthcare Companies: Veracyte (NASDAQ: VCYT) and Rocket Pharmaceuticals (NASDAQ: RCKT)

Michael Matson

Needham

€61.53

Buy

65.53%

Upside

Reiterated

09/15/26

Veracyte Acquisition of Convergent Genomics Bolsters Urology Franchise; Buy Rating Reiterated with Unchanged $69 Price Target

Keith Hinton

Freedom Capital Markets

€58.85

Buy

58.33%

Upside

Reiterated

09/15/26

Analysts Are Bullish on These Healthcare Stocks: Scholar Rock Holding (SRRK), Veracyte (VCYT)

Doug Schenkel

UBS

€46.37→€57.96

Buy

55.93%

Upside

Reiterated

09/09/26

Veracyte (VCYT) Gets a Buy from UBS

Kallum Titchmarsh

Morgan Stanley

€41.91→€39.23

Sell

5.55%

Upside

Assigned

08/04/26

Veracyte price target lowered to $44 from $47 at Morgan StanleyVeracyte price target lowered to $44 from $47 at Morgan Stanley

Mason Carrico

Stephens

€49.04

Buy

31.94%

Upside

Reiterated

08/04/26

Stephens Keeps Their Buy Rating on Veracyte (VCYT)

Kyle Mikson CFA

Canaccord Genuity

€53.5→€44.58

Hold

19.95%

Upside

Reiterated

08/03/26

Veracyte price target lowered to $50 from $60 at CanaccordVeracyte price target lowered to $50 from $60 at Canaccord

Subbu Nambi

Guggenheim

€57.96

Buy

55.93%

Upside

Reiterated

07/31/26

Guggenheim Reaffirms Their Buy Rating on Veracyte (VCYT)

Tycho Peterson

Jefferies

€62.42

Buy

67.92%

Upside

Reiterated

07/08/26

Jefferies Sticks to Its Buy Rating for Veracyte (VCYT)

Paige Chamberlain‏

Wolfe Research

€44.58→€49.04

Buy

31.94%

Upside

Assigned

06/01/26

Veracyte assumed with an Outperform at Wolfe ResearchVeracyte assumed with an Outperform at Wolfe Research

Lu Li

Bank of America Securities

€42.8→€46.37

Buy

24.74%

Upside

Reiterated

05/06/26

Veracyte price target raised to $52 from $48 at UBSVeracyte price target raised to $52 from $48 at UBS

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Westenberg

Piper Sandler

€48.15

Buy

29.54%

Upside

Reiterated

09/17/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Veracyte (NASDAQ: VCYT), IQVIA Holdings (NYSE: IQV) and Chemed (NYSE: CHE)

William Bonello

Craig-Hallum

―

Buy

―

Reiterated

09/15/26

Analysts Offer Insights on Healthcare Companies: OmniAb (NASDAQ: OABI), Veracyte (NASDAQ: VCYT) and Rocket Pharmaceuticals (NASDAQ: RCKT)

Matt Larew

William Blair

―

Buy

―

Reiterated

09/15/26

Analysts Offer Insights on Healthcare Companies: Veracyte (NASDAQ: VCYT) and Rocket Pharmaceuticals (NASDAQ: RCKT)

Michael Matson

Needham

€61.53

Buy

65.53%

Upside

Reiterated

09/15/26

Veracyte Acquisition of Convergent Genomics Bolsters Urology Franchise; Buy Rating Reiterated with Unchanged $69 Price Target

Keith Hinton

Freedom Capital Markets

€58.85

Buy

58.33%

Upside

Reiterated

09/15/26

Analysts Are Bullish on These Healthcare Stocks: Scholar Rock Holding (SRRK), Veracyte (VCYT)

Doug Schenkel

UBS

€46.37→€57.96

Buy

55.93%

Upside

Reiterated

09/09/26

Veracyte (VCYT) Gets a Buy from UBS

Kallum Titchmarsh

Morgan Stanley

€41.91→€39.23

Sell

5.55%

Upside

Assigned

08/04/26

Veracyte price target lowered to $44 from $47 at Morgan StanleyVeracyte price target lowered to $44 from $47 at Morgan Stanley

Mason Carrico

Stephens

€49.04

Buy

31.94%

Upside

Reiterated

08/04/26

Stephens Keeps Their Buy Rating on Veracyte (VCYT)

Kyle Mikson CFA

Canaccord Genuity

€53.5→€44.58

Hold

19.95%

Upside

Reiterated

08/03/26

Veracyte price target lowered to $50 from $60 at CanaccordVeracyte price target lowered to $50 from $60 at Canaccord

Subbu Nambi

Guggenheim

€57.96

Buy

55.93%

Upside

Reiterated

07/31/26

Guggenheim Reaffirms Their Buy Rating on Veracyte (VCYT)

Tycho Peterson

Jefferies

€62.42

Buy

67.92%

Upside

Reiterated

07/08/26

Jefferies Sticks to Its Buy Rating for Veracyte (VCYT)

Paige Chamberlain‏

Wolfe Research

€44.58→€49.04

Buy

31.94%

Upside

Assigned

06/01/26

Veracyte assumed with an Outperform at Wolfe ResearchVeracyte assumed with an Outperform at Wolfe Research

Lu Li

Bank of America Securities

€42.8→€46.37

Buy

24.74%

Upside

Reiterated

05/06/26

Veracyte price target raised to $52 from $48 at UBSVeracyte price target raised to $52 from $48 at UBS

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

KNSAKiniksa Pharmaceuticals

OMCLOmnicell

AXGNAxoGen

ONCBeOne Medicines

AHCOAdaptHealth

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Veracyte

3 Months

Kallum TitchmarshMorgan Stanley

Success Rate

4/6 ratings generated profit

Average Return

+3.18%

Copying Kallum Titchmarsh's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +3.18% per trade.

1 Year

William BonelloCraig-Hallum

Success Rate

7/8 ratings generated profit

Average Return

+23.00%

Copying William Bonello's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +23.00% per trade.

2 Years

William BonelloCraig-Hallum

Success Rate

8/8 ratings generated profit

Average Return

+35.38%

Copying William Bonello's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +35.38% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

12V Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 12V has received 9 Buy Ratings, 1 Hold Ratings, and 1 Sell Ratings. 12V average Analyst price target in the past 3 months is 52.16.

Each month's total comprises the sum of three months' worth of ratings.

12V Financial Forecast

12V Earnings Forecast

Next quarter’s earnings estimate for 12V is €0.37 with a range of €0.31 to €0.40. The previous quarter’s EPS was €0.48. 12V beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 12V has Performed in-line its overall industry.

12V Sales Forecast

Next quarter’s sales forecast for 12V is €131.04M with a range of €129.03M to €132.33M. The previous quarter’s sales results were €133.86M. 12V beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 12V has Performed in-line its overall industry.

12V Stock Forecast FAQ

What is DE:12V’s average 12-month price target, according to analysts?

Based on analyst ratings, Veracyte’s 12-month average price target is 52.16.

What is DE:12V’s upside potential, based on the analysts’ average price target?

Veracyte has 40.34% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Veracyte a Buy, Sell or Hold?

Veracyte has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 1 hold ratings and 1 sell ratings.

What is Veracyte’s share price target?

The average share price target for Veracyte is 52.16. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €61.53 ,and the lowest forecast is €39.23. The average share price target represents 40.34% Increase from the current price of €37.17.

What do analysts say about Veracyte?

Veracyte’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of Veracyte?

To buy shares of DE:12V, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Veracyte (12V) Stock Forecast & Price Target

12V Analyst Ratings

12V Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Veracyte

12V Analyst Recommendation Trends

12V Financial Forecast

12V Earnings Forecast

12V Sales Forecast

12V Stock Forecast FAQ

Detailed List of Analyst Forecasts